Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls

What Was Tested

Researchers studied Vasopressin in this randomized controlled trial publication.

This study aimed to evaluate bone turnover markers in patients with AVP-D compared to individuals with primary polydipsia (PP) and healthy controls (HC).

Why It Was Studied

Arginine vasopressin (AVP) and oxytocin are neurohormones with opposing effects on bone in preclinical models, while their relevance in humans remains uncertain.

Who Took Part

The study group was 46 participants.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

This was a secondary analysis of the prospective URANOS Trial (NCT05890690) conducted from June 2023 to June 2024.

All individuals were assessed for bone resorption (C-terminal telopeptide of type I collagen [CTX]) and bone formation (N-terminal propeptide of type I collagen [P1NP]) markers, as well as 25OH-vitamin D, serum calcium, and phosphate.

The bone formation index (defined as P1NP/CTX ratio) was calculated.

What Was Measured

The subject headings attached to it are Arginine Vasopressin, Biomarkers, Bone Remodeling, Bone Resorption, Case-Control Studies, Collagen Type I and Polyuria.

Author keywords: AVP deficiency, CTX, P1NP, central diabetes insipidus, osteoporosis and oxytocin.

What This Means in Plain Language

The paper is a randomized study of Vasopressin in 46 participants.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vasopressin compound page, all human trials.